Paper Details

  1. Home
  2. Paper Details

Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Author: Al-KatebHussam, AnwerFaiz, BaigMirza, CarewJennifer, Cavalcante ParrNadia Nunes, GeeKevin Mathew, IftikharAhmad, McBrideAli, NawrockiSteffan, RazzaqFaryal, RussAtlantis Dawn, SaeedSabina, SamarasChristy, ValentJason, ZarMuhammad Abu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Multiple myeloma is a complex cancer with various genetic changes that drive its progression and resistance to treatment. Researchers are identifying specific targets for new drugs, such as those that block certain pathways (RAS, BCL-2, JAK2, NF-κB, MDM2, PI3K/mTOR), or proteins (cyclin D1, MYC, FGFR3). Medications that target these pathways are already in development or being used in combination with existing treatments. A better understanding of these pathways will help develop more personalized treatments for myeloma.
Paper Details　
Original Abstract of the Article :
Multiple myeloma (MM) is a genetically complex disease. Identification of mutations and aberrant signaling pathways that contribute to the progression of MM and drug resistance has potential to lead to specific targets and personalized treatment. Aberrant signal pathways include RAS pathway activati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31036508

データ提供：米国国立医学図書館（NLM）

The Future of Personalized Therapy in Multiple Myeloma: Targeting Aberrant Signaling Pathways

The vast desert of multiple myeloma research is a complex and challenging landscape, requiring a personalized approach to treatment. This study, like a caravan exploring new strategies, investigates the potential of targeting aberrant signaling pathways in [multiple myeloma (MM)], a genetically complex disease. The researchers, like seasoned explorers, identified various mutated pathways and potential targets for personalized therapy, including [RAS, BRAF, BCL-2, JAK2, NF-κB, MDM2, PI3K/mTOR, CCND1, MYC, FGFR3, BET]. Their findings, like a shimmering oasis in the desert, highlight the potential for personalized therapies to effectively treat MM and overcome drug resistance.

A New Oasis for Personalized Multiple Myeloma Treatment

This research, like a beacon guiding travelers through a challenging terrain, underscores the promise of personalized therapy in multiple myeloma. By targeting specific aberrant signaling pathways, we can develop more effective treatments tailored to the individual needs of each patient. This represents a significant advancement in the fight against this complex disease.

A Personalized Approach to Cancer Treatment

This study encourages us to embrace a more personalized approach to cancer treatment. By understanding the unique genetic makeup of each patient, we can develop targeted therapies that offer greater efficacy and minimize side effects. This personalized approach to cancer treatment represents a significant shift in the desert of oncology, offering a more hopeful and effective path for patients.

Dr. Camel's Conclusion

This study is a testament to the ever-evolving landscape of cancer research. The potential of personalized therapy in multiple myeloma, by targeting specific aberrant signaling pathways, offers a promising new oasis in the desert of cancer treatment. Remember, by embracing a personalized approach and continuing to explore new avenues of research, we can provide more effective and compassionate care for patients facing this challenging disease.

Date :
  1. Date Completed 2020-08-04
  2. Date Revised 2020-08-04
Further Info :

Pubmed ID

31036508

DOI: Digital Object Identifier

NIHMS1525331

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.